- Home
- AIRI vs COCP Comparison
AIRI vs COCP Comparison
Compare AIRI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- COCP
- Stock Information
- Founded
- AIRI 1979
- COCP N/A
- Country
- AIRI United States
- COCP United States
- Employees
- AIRI N/A
- COCP N/A
- Industry
- AIRI Military/Government/Technical
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- COCP Health Care
- Exchange
- AIRI Nasdaq
- COCP Nasdaq
- Market Cap
- AIRI 15.4M
- COCP 18.3M
- IPO Year
- AIRI N/A
- COCP N/A
- Fundamental
- Price
- AIRI $4.35
- COCP $1.99
- Analyst Decision
- AIRI
- COCP Strong Buy
- Analyst Count
- AIRI 0
- COCP 1
- Target Price
- AIRI N/A
- COCP $7.00
- AVG Volume (30 Days)
- AIRI 45.8K
- COCP 14.9K
- Earning Date
- AIRI 11-14-2024
- COCP 11-13-2024
- Dividend Yield
- AIRI N/A
- COCP N/A
- EPS Growth
- AIRI N/A
- COCP N/A
- EPS
- AIRI N/A
- COCP N/A
- Revenue
- AIRI $53,657,000.00
- COCP N/A
- Revenue This Year
- AIRI $9.26
- COCP N/A
- Revenue Next Year
- AIRI $8.73
- COCP N/A
- P/E Ratio
- AIRI N/A
- COCP N/A
- Revenue Growth
- AIRI 3.31
- COCP N/A
- 52 Week Low
- AIRI $3.00
- COCP $1.33
- 52 Week High
- AIRI $9.44
- COCP $3.10
- Technical
- Relative Strength Index (RSI)
- AIRI 38.83
- COCP 51.27
- Support Level
- AIRI $4.11
- COCP $1.83
- Resistance Level
- AIRI $4.60
- COCP $2.07
- Average True Range (ATR)
- AIRI 0.26
- COCP 0.11
- MACD
- AIRI 0.02
- COCP -0.01
- Stochastic Oscillator
- AIRI 30.77
- COCP 44.74
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).